Webinar | JAGntd | Country's Perspective: Introduction of Pediatric Praziquantel for Schistosomiasis in Tanzania
This webinar examines challenges to introduce a new NTD drug from a country perspective. Pediatric praziquantel, though it is not yet approved by health regulatory authorities, is expected to provide a solution to treat children infected with schistosomiasis. This session will first invite Dr. Steinmann From the Pediatric Praziquantel Consortium to review the consortium's global access strategies. Then, we focus on Tanzania. Dr. Yahya-Malima and Dr. Kazyoba will explain a project to get this country ready for the future introduction of pediatric praziquantel.
This session will deepen your understanding of the preparations that can be made in a country level for accepting new drugs prior to their approval, is supported by the Access and Delivery Partnership, funded by the Government of Japan. Focusing on the necessary communications and community engagement.
- Peter Steinmann; Swiss Tropical and Public Health Institute, Pediatric Praziquantel Consortium
- Khadija Innocensia Yahya-Malima; Muhimbili University of Health and Allied Sciences, Tanzania
- Paul Erasto Kazyoba; National Institute for Medical Research, Tanzania.